Understanding Melanotan I Cycling: What the Research Says

Melanotan I at a glance:

• Drug class: Cosmetic peptide
• Route: topical for most; injectable melanotans are unlicensed
• Typical frequency: daily topical application typical
• Half-life: topical residence time varies

Online "cycle" guides for Melanotan I are extrapolations from research dosing, not evidence-based recommendations. We explain the difference, and what the published research actually shows, below.

What "Cycle" Means in Peptide Discussions

In research-peptide and GHS communities, a "cycle" usually refers to a defined period of administration (often 8-12 weeks) followed by a break. The rationale draws on receptor desensitization theory and historical bodybuilding practice.

For Melanotan I: no formal cycling protocol has been studied in human RCTs. Online protocols are extrapolations, not evidence-based recommendations.

Published Research Dosing

Cosmetic peptides in skincare are regulated as cosmetics, not drugs. Injectable melanotans are not FDA-approved.

When peptides are studied in research, the doses come from animal-to-human translation, prior pharmacokinetic data, and trial designs that can't be assumed to apply to individual self-administration.

What Researchers Actually Do

In the published research literature on Melanotan I:

• Doses are typically expressed in mcg/kg or fixed mg amounts
• Administration routes match what was tested for safety
• Duration is bounded by the trial protocol (often 8-12 weeks)
• Outcome measurement is structured and pre-specified

These are not personal protocols; they're trial designs.

Why We Don't Publish Self-Administration Protocols

Three reasons:

1. Compound purity and identity are not verifiable for material from grey-market sources
2. Individual response to non-FDA-approved compounds is not characterized at the population level
3. Liability and safety realities make specific instructions inappropriate for an informational site

For Melanotan I specifically, the evidence base is too thin to support specific guidance.

What to Do Instead

If you're researching Melanotan I because of a specific health goal, the more productive path is usually:

• Identify the underlying issue (musculoskeletal, metabolic, etc.)
• Look at FDA-approved options that address it
• Talk to a clinician with relevant expertise
• Consider research-peptide options only as a last resort, with clear understanding of unknowns

Risks to Understand

• atypical melanocytic lesions and other adverse events have been reported with injectable melanotans

These are compound to the risks of unregulated supply (purity, contamination, dosing accuracy).

Bottom Line

For Melanotan I, the published research is the right reference point. Anything beyond that is opinion.

Frequently Asked Questions

Related Reading

• What Is Melanotan I? Everything You Should Know Before Starting
• What Nobody Tells You About Melanotan I Side Effects
• Melanotan I Results: What the Real Numbers Show in 2026
• How Much Does Melanotan I Really Cost? The Honest Breakdown
• Melanotan II Explained: How It Works and Who It's For
• Melanotan II Side Effects in 2026: Real Reports, Real Solutions

Sources

• Pickart L. The Human Tri-Peptide GHK and Tissue Remodeling. J Biomater Sci Polym Ed 2008;19:969.
• Habbema L et al. Risks of Unregulated Use of Alpha-Melanocyte-Stimulating Hormone Analogues. Br J Dermatol 2017;176:633.

This page is informational only and is not medical advice or a recommendation for self-administration of any compound.